Rett Syndrome Drug DAYBUE Expands to New Markets
Adults and caregivers in more countries may gain access as sales of trofinetide grow.
Updated on Nov. 5, 2026 in Alzheimer’s

Neuren Pharmaceuticals raised its full-year 2026 income guidance for trofinetide to US$91 million to US$93 million, up from US$53 million to US$56 million. The upgrade follows strong third-quarter sales of DAYBUE, the trofinetide-based treatment for Rett syndrome, by partner Acadia Pharmaceuticals.
Why it matters
Trofinetide is one of few approved medicines for Rett syndrome, a rare neurodevelopmental disorder, so its commercial growth signals expanding access for patients in new markets. The guidance change was driven by a milestone payment tied to DAYBUE's launch in Germany and by Acadia's rising sales, both of which indicate broader uptake of the therapy outside the United States.
These figures come from company financial reporting and guidance rather than clinical trial results, so they measure commercial performance rather than treatment efficacy. Sales and royalty figures are compared against prior-year and prior-quarter periods, but the source does not describe patient numbers or outcomes.
The players
Neuren Pharmaceuticals
An Australian biopharmaceutical company focused on neurodevelopmental and neurological disorders, and the developer of trofinetide.
Acadia Pharmaceuticals
A US biopharmaceutical company that markets DAYBUE for Rett syndrome and holds global commercialization rights to trofinetide.
The details
Trofinetide is the active ingredient in DAYBUE, and Neuren receives royalties and milestone payments from sales made by its partner Acadia Pharmaceuticals. The US$35 million milestone payment was triggered when DAYBUE launched in Germany in October 2026, which expanded the drug's availability to a new European market. Because royalty income scales with sales, Acadia's strong third-quarter performance flowed directly into Neuren's higher guidance.
Timeline
October 2026: DAYBUE launched in Germany, triggering a US$35 million milestone payment.
Q3 2026: Acadia reported DAYBUE net sales of US$140 million.
November 5, 2026: Neuren announced its upgraded full-year 2026 guidance.
2027: Neuren plans a regulatory submission for trofinetide in Japan.
March 2041: A newly allowed US patent covering weight-banded dosing extends intellectual property protection to this date.
Health Landscape
Rett syndrome has historically lacked approved disease-modifying treatments, so DAYBUE's commercial expansion marks a shift toward broader availability of a therapy for this rare disorder. The move into European and potential Japanese markets reflects a pattern of rare-disease drugs expanding internationally after initial approval in the United States.
Families and caregivers of people with Rett syndrome may find that DAYBUE is becoming available in more countries as sales and approvals expand. Anyone with questions about whether this treatment could fit a specific situation should discuss it with a neurologist or the patient's treating physician.
The takeaway
Commercial growth of a rare-disease therapy like trofinetide shows how international approvals can widen access over time. Readers following Rett syndrome treatment should watch for regulatory decisions in new markets, such as Japan, and ask a specialist about current treatment options.
What happens next
Neuren plans to submit trofinetide for regulatory review in Japan during 2027, with a potential launch there in 2028 subject to approval.
Further reading
For broader context on neurological conditions and their treatments, explore our Alzheimer’s coverage.


